Clinical Trial Update: Investigating Efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Ablation Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating two three-month degarelix dosing regimens for prostate cancer patients requiring androgen deprivation therapy, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• degarelix (degarelix)

Snippet

Sponsor: Ferring Pharmaceuticals | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2011-03-03